Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 5297980, 10 pages
https://doi.org/10.1155/2018/5297980
Research Article

JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus

1Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy
2National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
3Department of Neurology and Psychiatry, Multiple Sclerosis Center, Sapienza University, Rome, Italy
4Department of Medical and Surgical Sciences and Biotechnology, Neurovascular Diagnosis Unit, Section of Neurology, Sapienza University, Rome, Italy

Correspondence should be addressed to Marco Iannetta; ti.imni@attennai.ocram

Received 17 September 2017; Accepted 29 January 2018; Published 27 February 2018

Academic Editor: Robert Movérare

Copyright © 2018 Maria A. Zingaropoli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Atlas of MS [Internet], “MS International Federation,” https://www.msif.org/about-us/who-we-are-and-what-we-do/advocacy/atlas/.
  2. S. L. Hauser, J. R. Chan, and J. R. Oksenberg, “Multiple sclerosis: Prospects and promise,” Annals of Neurology, vol. 74, no. 3, pp. 317–327, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Ffrench-Constant, “Pathogenesis of multiple sclerosis,” The Lancet, vol. 343, no. 8892, pp. 271–275, 1994. View at Google Scholar
  4. J. L. Baron, J. A. Madri, N. H. Ruddle, G. Hashim, and C. A. Janeway, “Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenehyma,” The Journal of Experimental Medicine, vol. 177, no. 1, pp. 57–68, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. R. R. Lobb and M. E. Hemler, “The pathophysiologic role of α4 integrins in vivo,” The Journal of Clinical Investigation, vol. 94, no. 5, pp. 1722–1728, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. O. J. Léger, T. A. Yednock, L. Tanner, H. C. Horner, D. K. Hines, S. Keen et al., “Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis,” Human Antibodies, vol. 8, no. 1, pp. 3–16, 1997. View at Google Scholar
  7. T. A. Yednock, C. Cannon, L. C. Fritz, F. Sanchez-Madrid, L. Steinmant, and N. Karin, “Prevention of experimental autoimmune encephalomyelitis by antibodies against 41 integrin,” Nature, vol. 356, no. 6364, pp. 63–66, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. P. O'Connor, A. Goodman, L. Kappos et al., “Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study,” Neurology, vol. 83, no. 1, pp. 78–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Butzkueven, L. Kappos, F. Pellegrini, M. Trojano, H. Wiendl, RN. Patel et al., “TYSABRI Observational Program (TOP) Investigators. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 85, no. 11, pp. 1190–1197, 2014. View at Google Scholar
  10. C. H. Polman, P. W. OConnor, E. Havrdova, M. Hutchinson, L. Kappos, and D. H. Miller, “AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis,” The New England Journal of Medicine, vol. 354, no. 9, pp. 899–910, 2006. View at Google Scholar
  11. R. A. Rudick, W. H. Stuart, P. A. Calabresi et al., “SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis,” The New England Journal of Medicine, vol. 354, no. 9, pp. 911–923, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Langer-Gould, S. W. Atlas, A. J. Green, A. W. Bollen, and D. Pelletier, “Progressive multifocal leukoencephalopathy in a patient treated with natalizumab,” The New England Journal of Medicine, vol. 353, no. 4, pp. 375–381, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. B. K. Kleinschmidt-DeMasters and K. L. Tyler, “Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis,” The New England Journal of Medicine, vol. 353, no. 4, pp. 369–374, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Van Assche, M. Van Ranst, R. Sciot et al., “Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease,” The New England Journal of Medicine, vol. 353, no. 4, pp. 362–368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Hegen, M. Auer, G. Bsteh et al., “Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study,” PLoS ONE, vol. 12, no. 3, Article ID e0174005, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. I. J. Koralnik, “Finger pointing to JC virus: A tale two indexes,” Annals of Neurology, vol. 76, no. 6, pp. 789–791, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Iannetta, M. A. Zingaropoli, A. Bellizzi et al., “Natalizumab affects T-Cell phenotype in multiple sclerosis: Implications for JCV reactivation,” PLoS ONE, vol. 11, no. 8, Article ID e0160277, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Frisullo, R. Iorio, D. Plantone et al., “CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment,” Mult Scler Houndmills Basingstoke Engl, vol. 17, no. 5, pp. 556–566, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Putzki, M. K. Baranwal, B. Tettenborn, V. Limmroth, and E. Kreuzfelder, “Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells,” European Neurology, vol. 63, no. 5, pp. 311–317, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Khademi, L. Bornsen, F. Rafatnia et al., “The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers,” European Journal of Neurology, vol. 16, no. 4, pp. 528–536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Khademi, D. Stol, T. Olsson, and E. Wallström, “Induction of systemic TNFα in Natalizumab-treated multiple sclerosis,” European Journal of Neurology, vol. 15, no. 3, pp. 309–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Carotenuto, G. Scalia, F. Ausiello et al., “CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients,” Journal of Neuroimmunology, vol. 309, pp. 47–50, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. B. R. Nielsen, R. Ratzer, L. Börnsen, M. R. von Essen, and Christensen. J. r, “Characterization of naïve, memory and effector T cells in progressive multiple sclerosis,” Journal of Neuroimmunology, vol. 310, pp. 17–25, 2017. View at Google Scholar
  24. A. Bellizzi, E. Anzivino, D. M. Rodio et al., “Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: An observational study,” Virology Journal, vol. 10, no. 298, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. J. R. Berger, S. A. Houff, J. Gurwell, N. Vega, C. S. Miller, and R. J. Danaher, “JC virus antibody status underestimates infection rates,” Annals of Neurology, vol. 74, no. 1, pp. 84–90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. E. O. Major, E. Frohman, and D. Douek, “JC viremia in natalizumab-treated patients with multiple sclerosis,” The New England Journal of Medicine, vol. 368, no. 23, pp. 2240-2241, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Outteryck, H. Zéphir, J. Salleron et al., “JC-virus seroconversion in multiple sclerosis patients receiving natalizumab,” Multiple Sclerosis Houndmills Basingstoke Engl, vol. 20, no. 7, pp. 822–829, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. M.-S. G. Brosseau, G. Stobbe, and A. Wundes, “Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay,” Neurology, vol. 86, no. 5, pp. 484–486, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Defer, D. Mariotte, N. Derache et al., “CD49d expression as a promising biomarker to monitor natalizumab efficacy,” Journal of the Neurological Sciences, vol. 314, no. 1-2, pp. 138–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Puñet-Ortiz, J. V. Hervás-García, A. Teniente-Serra et al., “Monitoring CD49d receptor occupancy: A method to optimize and personalize natalizumab therapy in multiple sclerosis patients,” Cytometry Part B - Clinical Cytometry, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Planas, I. Jelčić, S. Schippling, R. Martin, and M. Sospedra, “Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis,” European Journal of Immunology, vol. 42, no. 3, pp. 790–798, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. O. Stüve, C. M. Marra, K. R. Jerome et al., “Immune surveillance in multiple sclerosis patients treated with natalizumab,” Annals of Neurology, vol. 59, no. 5, pp. 743–747, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Gheuens, E. Bord, S. Kesari et al., “Role of CD4 + and CD8 + T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome,” Journal of Virology, vol. 85, no. 14, pp. 7256–7263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. B. O. Khatri, J. Garland, J. Berger et al., “The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk,” Multiple Sclerosis and Related Disorders, vol. 4, no. 4, pp. 377–379, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. Q. Wu, Q. Wang, G. Mao, C. A. Dowling, S. K. Lundy, and Y. Mao-Draayer, “Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1/Th17 and Th2 in multiple sclerosis patients,” The Journal of Immunology Baltim Md 1950, vol. 198, no. 8, pp. 3069–3080, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. R.-J. Gieselbach, A. H. Muller-Hansma, M. T. Wijburg et al., “Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases,” Journal of Neurology, vol. 264, no. 6, pp. 1155–1164, 2017. View at Publisher · View at Google Scholar · View at Scopus